Biotech Values

[exwannabe]

No, we cannot say that. Teva might be able to get a preliminary injunction to block the launch of generic Copaxone; however, the likelihood of Teva’s getting a PI will be diminished if the Judge believes Teva is unlikely to prevail in the Copaxone trial.

My understanding was that most of these PI motions are dismissed for the lack of irreparable damage regardless of other criterion.

On my mental calendar I will leave both penciled in as very unlikely.